Lantheus Holdings, Inc. $LNTH Shares Bought by Reinhart Partners LLC.

Reinhart Partners LLC. raised its holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 16.4% in the 2nd quarter, according to the company in its most recent filing with the SEC. The firm owned 1,403,659 shares of the medical equipment provider’s stock after acquiring an additional 197,719 shares during the quarter. Lantheus makes up about 3.9% of Reinhart Partners LLC.’s portfolio, making the stock its 2nd largest holding. Reinhart Partners LLC. owned about 2.03% of Lantheus worth $114,905,000 at the end of the most recent quarter.

A number of other hedge funds also recently modified their holdings of LNTH. Mirae Asset Global Investments Co. Ltd. grew its holdings in Lantheus by 3.4% during the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 12,084 shares of the medical equipment provider’s stock worth $1,162,000 after acquiring an additional 400 shares during the period. State of Alaska Department of Revenue increased its holdings in Lantheus by 2.7% in the first quarter. State of Alaska Department of Revenue now owns 8,142 shares of the medical equipment provider’s stock worth $794,000 after purchasing an additional 215 shares in the last quarter. GAMMA Investing LLC lifted its stake in Lantheus by 12,517.1% in the first quarter. GAMMA Investing LLC now owns 128,442 shares of the medical equipment provider’s stock valued at $12,536,000 after buying an additional 127,424 shares during the period. Select Equity Group L.P. lifted its holdings in shares of Lantheus by 899.2% in the first quarter. Select Equity Group L.P. now owns 100,843 shares of the medical equipment provider’s stock valued at $9,842,000 after purchasing an additional 90,751 shares in the last quarter. Finally, Swedbank AB boosted its position in shares of Lantheus by 11.0% during the first quarter. Swedbank AB now owns 1,228,743 shares of the medical equipment provider’s stock valued at $119,925,000 after buying an additional 121,500 shares during the last quarter. Institutional investors and hedge funds own 99.06% of the company’s stock.

Insider Transactions at Lantheus

In other news, insider Rajiv A. Patel sold 3,365,000 shares of the stock in a transaction dated Wednesday, August 20th. The stock was sold at an average price of $56.15, for a total transaction of $188,944,750.00. Following the transaction, the insider directly owned 3,477,227 shares in the company, valued at approximately $195,246,296.05. This represents a 49.18% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Farallon Partners L. L C/Ca sold 3,365,000 shares of the company’s stock in a transaction that occurred on Wednesday, August 20th. The stock was sold at an average price of $56.15, for a total value of $188,944,750.00. Following the completion of the sale, the insider directly owned 3,477,227 shares of the company’s stock, valued at approximately $195,246,296.05. This represents a 49.18% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 6,812,000 shares of company stock valued at $382,427,380 over the last quarter. Company insiders own 2.00% of the company’s stock.

Lantheus Stock Up 0.5%

LNTH stock opened at $51.98 on Wednesday. The company’s 50 day moving average is $62.83 and its 200 day moving average is $80.71. The stock has a market cap of $3.53 billion, a price-to-earnings ratio of 13.82 and a beta of 0.15. The company has a current ratio of 4.29, a quick ratio of 4.07 and a debt-to-equity ratio of 0.49. Lantheus Holdings, Inc. has a 1-year low of $47.25 and a 1-year high of $118.21.

Lantheus (NASDAQ:LNTH) last released its quarterly earnings results on Wednesday, August 6th. The medical equipment provider reported $1.57 EPS for the quarter, missing analysts’ consensus estimates of $1.65 by ($0.08). The company had revenue of $378.05 million during the quarter, compared to analysts’ expectations of $389.69 million. Lantheus had a return on equity of 34.06% and a net margin of 17.82%.Lantheus’s quarterly revenue was down 4.1% on a year-over-year basis. During the same period in the prior year, the firm earned $1.80 EPS. Sell-side analysts predict that Lantheus Holdings, Inc. will post 6.01 EPS for the current fiscal year.

Analyst Ratings Changes

Several analysts have recently issued reports on LNTH shares. B. Riley reduced their target price on shares of Lantheus from $109.00 to $84.00 and set a “buy” rating for the company in a research note on Tuesday. Mizuho lowered their price target on shares of Lantheus from $120.00 to $70.00 and set an “outperform” rating on the stock in a report on Thursday, August 7th. William Blair reiterated a “market perform” rating on shares of Lantheus in a research note on Wednesday, July 16th. JMP Securities decreased their target price on Lantheus from $112.00 to $73.00 and set a “market outperform” rating for the company in a research report on Thursday, August 7th. Finally, Truist Financial set a $63.00 target price on Lantheus and gave the company a “hold” rating in a research note on Monday, August 11th. Five research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $85.50.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.